© 2025 Inizio Evoke Comms. All Rights Reserved.
Mythic Therapeutics
Leave less to chance: sending ADCs to their targets with FateControl
Key Highlights
- Helping ADCs Find Their Fate: Mythic is pioneering self-navigating ADCs. Its approach manipulates the trafficking of antibody drug conjugates in cells with its FateControl platform to increase uptake in tumors while avoiding payload release in healthy tissues – potentially increasing therapeutic potency and improving tolerability.
- Well-Known Target, Common in NSCLC? It’s KisMET: Therapeutic pipeline is led by KisMET-01 clinical study of MYTX-011, a cMET-targeting ADC, for treatment of NSCLC where 70% of tumors have cMET over-expression. Mythic’s approach allows its ADCs to target cMET in patients with low- to – moderate target expression, a potential game changer as currently available ADCs require high target expression to be effective.
- Key Events in 2025: Data from KisMET-01 trial in NSCLC